Quantifying The Potential: Using Data-Driven Insights To Demonstrate Biotech Asset Value

By Meg Hooton, President, IQVIA Biotech, Todd Matthews, MBA, Senior Director, Corporate Alliances, IQVIA and Dean Giovanniello, RPH, MBA, Sr. Principal, Financial Institutions & Brand and Commercial Strategy Consulting Services, IQVIA

In today’s competitive biotech landscape, demonstrating asset value requires more than scientific promise — it demands quantifiable evidence. Data-driven insights are essential for translating complex clinical and market variables into a clear, compelling value proposition.

By leveraging real-world data, predictive analytics, and comparative benchmarks, biotechs can validate differentiation, forecast market potential, and strengthen investor confidence. This approach not only supports strategic decision-making but also helps prioritize indications, optimize trial design, and anticipate regulatory hurdles. A robust evidence framework positions assets for success by aligning scientific innovation with commercial viability, ensuring stakeholders see both opportunity and scalability.

Explore practical strategies for using data to articulate value, mitigate risk, and accelerate development in an increasingly evidence-focused environment. Access the full resource to learn how data-driven methodologies can transform asset valuation and enhance investment appeal.